SCHEMBL6318974

SCHEMBL6318974

NC(=O)c1c(-c2ccncc2)noc1NC(=O)/C=C/c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.50
LMNA P02545 3/20 0.50
MAPK1 P28482 3/20 0.50
KDM4E B2RXH2 3/20 0.50
MAPT P10636 2/20 0.50
KMT2A Q03164 5/20 0.48
MEN1 O00255 3/20 0.48
GAA P10253 1/20 0.48
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
FLT3 P36888 1/20 0.45
EGFR P00533 1/20 0.44
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
TRPV1 Q8NER1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318983 1.00 SMN1; SMN2 (0.50) SMN1; SMN2LMNAMAPK1KDM4EMAPT
SCHEMBL6618974 0.91 SMN1; SMN2 (0.52) SMN1; SMN2LMNAMAPK1KDM4EMAPT
SCHEMBL6316405 0.83 FLT3 (0.47) SMN1; SMN2LMNAMAPK1KDM4EMAPT
SCHEMBL6322724 0.83 RAB9A (0.46) SMN1; SMN2LMNAKDM4EMAPTKMT2A
SCHEMBL6322734 0.83 RAB9A (0.46) SMN1; SMN2LMNAKDM4EMAPTKMT2A
SCHEMBL6316396 0.83 FLT3 (0.47) SMN1; SMN2LMNAMAPK1KDM4EMAPT
SCHEMBL6319728 0.80 TBK1 (0.52) SMN1; SMN2MAPK1KDM4EKMT2AMEN1
SCHEMBL6318109 0.79 MAPK14 (0.46) SMN1; SMN2MAPK1KDM4EMAPTKMT2A
SCHEMBL6317649 0.77 SMN1; SMN2 (0.54) SMN1; SMN2LMNAMAPK1KDM4EKMT2A
SCHEMBL6317514 0.75 KMT2A (0.45) SMN1; SMN2MAPK1KDM4EMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 SMN1; SMN2 2766/4885LMNA 3334/4885MAPK1 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.